Catalyst Pharmaceuticals (CPRX) Profit After Tax (2010 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Profit After Tax came in at $63.7 million in Q1 2026, up 12.51% YoY from $56.7 million in Q1 2025, and up 20.96% on a QoQ basis from $52.7 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Profit After Tax (2010 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 17 years of Profit After Tax data on file, last reported at $63.7 million in Q1 2026.
- Quarterly Profit After Tax rose 12.51% year-over-year to $63.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $221.3 million (up 12.18% YoY) and the FY2025 annual result came in at $214.3 million, up 30.78% from the prior year.
- Profit After Tax climbed to $63.7 million in Q1 2026, from $52.7 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $63.7 million in Q1 2026 to a low of -$30.8 million in Q3 2023.
- A 5-year average of $35.1 million and a median of $37.8 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2023 — Profit After Tax plunged 235.26% — and 2024, when it surged 242.63%.
- Tracing CPRX's Profit After Tax over 5 years: stood at $25.5 million in 2022, then soared by 36.8% to $34.8 million in 2023, then jumped by 60.53% to $55.9 million in 2024, then fell by 5.79% to $52.7 million in 2025, then grew by 20.96% to $63.7 million in 2026.
- The last three Profit After Tax figures came in at $63.7 million (Q1 2026), $52.7 million (Q4 2025), and $52.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 63.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.74 Mn |
| Dec 31, 2025 | 52.70 Mn |
| Sep 30, 2025 | 52.75 Mn |
| Jun 30, 2025 | 52.11 Mn |
| Mar 31, 2025 | 56.66 Mn |
| Dec 31, 2024 | 55.94 Mn |
| Sep 30, 2024 | 43.88 Mn |
| Jun 30, 2024 | 40.79 Mn |
| Mar 31, 2024 | 23.28 Mn |
| Dec 31, 2023 | 34.84 Mn |
| Sep 30, 2023 | -30.77 Mn |
| Jun 30, 2023 | 37.76 Mn |
| Mar 31, 2023 | 29.57 Mn |
| Dec 31, 2022 | 25.47 Mn |
| Sep 30, 2022 | 22.75 Mn |
| Jun 30, 2022 | 21.62 Mn |
| Mar 31, 2022 | 13.24 Mn |
| Dec 31, 2021 | 9.13 Mn |
| Sep 30, 2021 | 10.30 Mn |
| Jun 30, 2021 | 12.18 Mn |